Immune Oncology

Clinical Neuroscience

NOVEMBER 30, 2023

Pembrolizumab-induced peripheral nervous system damage: A combination of myositis/ myasthenia overlap syndrome and motor axonal polyneuropathy

ARMAN ÇAKAR, IBRAHIM KAMACI, ELIF Kocasoy ORHAN, HACER DURMUŞ, YEŞIM PARMAN

Immune-checkpoint inhibitors (ICI) are effective drugs in cancer treatment that block immune checkpoints and stimulate an attack on cancer cells. However, various side effects were reported with ICIs. Peripheral nervous system (PNS) side effects are three times more frequent than those in the central nervous system. A 63-year-old male patient was admitted to our department with a 10-day history of dyspnea, diplopia, and generalized weakness.

ENG 2023;76(11-12)

Lege Artis Medicinae

NOVEMBER 23, 2023

[The mRNA vaccine that changes the endgame – The chronicle of a Nobel Prize]

KOVÁCS Sándor

[ ]

HUN 2023;33(10-11)

Hypertension and nephrology

OCTOBER 30, 2023

[Analysis of the relationship of oncological biological treatments and high blood pressure]

HARISI Revekka

[Biological drugs-combined chemotherapy represents a real breakthrough in the effective treatment of locally advanced and metastatic cancer patients. One of the most common and clinically significant side effects of angiogenesis inhibition is the development of high blood pressure. The purpose of this review is to analyze the relationship between inhibitors of the vascular endothelial growth factor signaling pathway and hypertension. We review incidence of VEGF/VEGFR inhibitors induced hypertension, mechanisms of its development, importance of blood pressure values regular monitoring, possible treatment strategies, and effectiveness of prophylactic antihypertensive treatment. We compare the results of clinical studies to clarify the prognostic and predictive significance of blood pressure elevation during antiangiogenic treatment. Further research into the relationship between biological treatment and hypertension may lead to more effective treatment with longer survival and better quality of life in advanced cancer patients.]

HUN 2023;27(05)

Hypertension and nephrology

OCTOBER 30, 2023

[Double endothelin receptor inhibitors]

MÓCZÁR Csaba

[A common problem in the hypertension care is the treatment of cases that react difficultly to treatment, including resistant hypertension. The structure of the treatment is particularly challenging. Intensive research is underway in the field of developing new drugs that can be used in the treatment of resistant hypertension, one possibility being dual endothelin receptor inhibitors. In my article, based on the results of the recently published PRECISION study, I present the possible use of the drug group in this area.]

HUN 2023;27(05)

Hypertension and nephrology

OCTOBER 30, 2023

[Acute tubulointerstitial nephritis occurring during treatment with a B-RAF inhibitor in a patient with colorectal adenocarcinoma]

PAKSICZA Lilla, DOBI Deján, TAKÁCS Veronika, MÉSZÁROS Edina, TOKODI Zsófia, DEÁK György

[With the expansion of targeted biological treatments in oncology and the improvement in life expectancies, it is increasingly common to consider the long-term and short-term effects of anti-tumor agents on the kidneys, which significantly influence patient mortality and future oncological treatment options. B-RAF inhibitors are widely used, primarily in cases of malignant melanoma and colorectal cancers. We present the case of a young patient with colorectal adenocarcinoma treated with B-RAF (v-Raf murine sarcoma viral oncogene homolog B) and EGFR (epidermal growth factor) inhibitors as second line agents. During treatment, acute renal failure developed, necessitating hemodialysis. Renal biopsy confirmed acute tubulointerstitial nephritis, and we suspected the nephrotoxic effect of the B-RAF inhibitor as the underlying cause. Steroid treatment was initiated, but unfortunately, we lost the patient due to rapid progression of the malignant disease.]

HUN 2023;27(05)

Clinical Neuroscience

SEPTEMBER 30, 2023

Neurobehavioral impairments in ciprofloxacin- treated osteoarthritic adult rats

KÉKESI Gabriella , DUCZA Eszter , GÁLITY Hristifor , BÜKI Alexandra , TÓTH Kálmán , TUBOLY Gábor , HORVÁTH Gyöngyi

Ciprofloxacin (CIP) is a broad-spectrum antibiotic widely used in clinical practice to treat musculoskeletal infections. Fluoroquinolone-induced neurotoxic adverse events have been reported in a few case reports, all the preclinical studies on its neuropsychiatric side effects involved only healthy animals. This study firstly investigated the behavioral effects of CIP in an osteoarthritis rat model with joint destruction and pain.

ENG 2023;76(9-10)